奈达铂和多烯紫杉醇联合放疗治疗术后存在预后不良因素的宫颈癌  

Combined Radiotherapy with Nedaplatin and Docetaxel for Cervical Cancer Associated with Poor Prognostic Factors

作　　者：谢乍晴[1] 吴翊群[1] 叶丽华[1] 

机构地区：[1]泰州市人民医院妇产科,江苏泰州225300

出　　处：《实用临床医学（江西）》2014年第7期59-61,共3页Practical Clinical Medicine

摘　　要：目的观察奈达铂和多烯紫杉醇联合放射治疗术后存在预后不良因素的宫颈癌的临床效果。方法将146例术后存在预后不良因素的Ⅰa2—Ⅱa期宫颈癌患者按简单随机方法分为2组,每组73例。研究组采用奈达铂和多烯紫杉醇联合放射治疗,对照组采用顺铂和紫杉醇联合放射治疗。结果研究组和对照组的24个月生存率分别为93.15%(68/73)和84.93%(62/73),局部复发率分别为13.70%(10/73)和19.18%(14/73),远处转移率分别为6.85%(5/73)和10.96%(8/73),2组差异均有统计学意义(均P<0.05)。结论奈达铂和多烯紫杉醇联合放疗是一个治疗术后存在预后不良因素的宫颈癌患者的安全有效的方案。Objective To explore the clinical efficacy of combined radiotherapy with nedaplatin and docetaxel for cervical cancer associated with poor prognostic factors. Methods A total of 146Ⅰa2-Ⅱa cervical carcinoma patients with poor prognostic factors were randomized into two groups, with 73 patients in each group. The study group was given combined radiotherapy with nedaplatin and docetaxel. The control group was given combined radiotherapy with cisplatin and paclitaxel. Results The 2-year survival rate, local recurrence rate and distant metastasis rate were, respectively, 93.15%（68/73）,13.70%（10/73） and 6.85%（5/73） in study group, and 84.93%（62/73）,19.18%（14/73） and 10.96%（8/73） in control group. Differences were significant between the two groups （P〈0.05）. Conclusion The combined radiotherapy with nedaplatin and docetaxel is safe and effective for cervical cancer associated with poor prognostic factors.

关 键 词：宫颈肿瘤 化学疗法 放射治疗 多西紫杉醇 奈达铂 

分 类 号：R737.33[医药卫生—肿瘤]